Shares of Vical Inc VICL plunged more than 40% after a Phase III clinical trial shoed NV1FGF, the company's cardiovascular drug, to be immensely ineffective
VICL is currently trading down off lows at $2.66, down 31%
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in